Brian Horger, PhD
Brian A. Horger, PhD (Chief Executive Officer) has extensive experience in pharmaceutical and drug development, as well as CRO expertise. Dr. Horger began his career as a Research Scientist at Yale University School of Medicine. Subsequently he held industry positions at Genentech and Theravance Biopharma where he led Pharmacology drug discovery efforts for novel therapeutics in various indications including Parkinson’s Disease and smooth muscle disorders. Prior to joining InClin, Dr. Horger served as a Director of Business Development at MDS Pharma Services and Covance Early Clinical Services. Dr. Horger has a PhD in Neuroscience from Texas A&M University.
George F. Faurot (Chief Operating Officer) is responsible for the planning, implementation, and execution of Phase 1 to 3 clinical development programs for multiple pharmaceutical sponsors, 3 of which resulted in successful NDA approvals. He started his career at Syntex Research conducting pre-clinical toxicology drug development research where he moved into the clinical research arena at Syntex, Matrix Pharmaceutical and Oculex Pharmaceuticals. Mr. Faurot has a BS in environmental toxicology from the University of California at Davis.
Taylor T. Kilfoil (Cofounder and Chief International Officer) is the managing director of InClin PTY LTD located in Sydney Australia. Mr. Kilfoil has 25+ years of pharmaceutical and biotech industry experience. Since co-founding InClin in 1998, Mr. Kilfoil has held a wide spectrum of senior level consultant positions at multiple pharmaceutical and biotechnology companies where he provided both clinical operations and project management support for their domestic and international clinical development programs. He started his career at Syntex Research conducting pre-clinical pharmacology drug development research where he moved into the clinical research arena at CardioGenesis, Serono Australia and Syntex Australia. Mr. Kilfoil has extensive experience in Phase 1 to 3 drug development. Mr. Kilfoil has a BS in psychobiology from Saint John’s University.
Arnold G. Wong (Cofounder and Chief Financial Officer) has hands-on experience in pre-clinical pharmacology drug development and extensive experience in clinical project management. He brings over thirty years of experience to an organization recognized for its commitment to quality, clinical experience and high employee retention. He began his career as a research scientist at Cardima, Inc., COR Therapeutics, and Syntex Research. Mr. Wong has a BS in physiology from the University of California at Davis.
Charles Du Mond, PhD
Charles Du Mond, PhD (Senior Vice President, Biometrics) has 30 years of experience working in the biotechnology, pharmaceutical, medical device, and CRO industries, providing study design, data management, clinical pharmacokinetics, statistical analysis, regulatory support (strategy, submissions, defense and approval), product development plans, and data safety monitoring boards. He started his career at Syntex Research working in HIV/AIDS, antiviral products, and infectious disease. He went on to Liposome Technology (later renamed SEQUUS), then founded a CRO, Pacific Research Associates (PRA) with 3 others. After 5 years, ICON Clinical Research acquired PRA and he stayed with ICON for another 13 years. During these years, he supported oncology, ophthalmology, analgesics, cardiology, nephrology, immunology, and gastro-intestinal products. For the three years prior to InClin, he served as Vice President of Biometrics at Relypsa. Dr. Du Mond received his MS and PhD in Statistics from The University of Iowa. He also has a BA in English and Mathematics/Computer Science from Central College in Pella, Iowa.
Tara Weihmiller (Vice President, Clinical Operations) is a global operations leader with a solid reputation for delivering inventive operational strategies and client-focused solutions with 20+ years of experience in the biopharmaceutical industry overseeing Project Management, Monitoring and study startup. Over the course of her career, Ms. Weihmiller has provided leadership and oversight of hundreds of phase 1 – 4 trials across multiple therapeutic areas including Oncology, Respiratory, Neurology, Infectious Disease, Dermatology, Transplant, and Device. Working on trials from a site, sponsor and CRO perspective, Ms. Weihmiller understands the complexities and challenges for those involved in clinical development. Ms. Weihmiller has spent the last 12 years in leadership positions (Novartis Director of Operations, Covance Executive Director) building customized client/team infrastructures to decrease operating costs and specializing in process improvements with change management implementation enabling teams to make quick data-driven decisions.
Debora “Deb” Manuel (Vice President, Clinical Data Management) has extensive experience in the design, conduct, and analysis of clinical research studies. Ms. Manuel has over 20 years of data management experience in all phases of clinical trials in both the CRO and Sponsor environments. She has experience with numerous complicated clinical studies, and has a thorough understanding of details necessary to ensure quality data and adherence to good practices in data management. Ms. Manuel has a BS in Information Systems from the University of San Francisco.
Kim Frieze, PharmD
Kimberly A. Frieze, PharmD (Senior Vice President, Medical communications) has over 24 years’ experience in the biopharmaceutical industry, focusing in the areas of clinical research, regulatory affairs, and medical writing for drug and biologic products. Prior to joining InClin, Dr. Frieze spent 12 years at Cardinal Health Regulatory Sciences (formerly Beckloff Associates) where she was a Director of Medical Writing, managing a large team of medical writers and contributing to multiple IND, NDA, BLA, and ANDA applications. Prior to Cardinal Health, Dr. Frieze was a Principle Medical Writing Scientist at Quintiles for 5 years and a Senior Medical Writer/Senior Clinical Research Associate at Hoechst Marion Roussel (formerly Marion Merrell Dow and Marion Laboratories) for 7 years. Prior to entering the pharmaceutical industry, Dr. Frieze worked for 5 years as a clinical pharmacist, focusing in clinical oncology. Dr. Frieze is a registered pharmacist in Kansas and a member of the American Medical Writer’s Association (AMWA) and Drug Information Association (DIA). She received a doctorate in pharmacy (PharmD) and a bachelor’s degree in pharmacy from the University of Kansas School of Pharmacy in Lawrence, KS.
Tony Cruz, DVM
Tony Cruz (Vice President, Quality Assurance) has over 20 years of industry experience in quality and regulatory compliance. Dr. Cruz previously held the positions of Senior Director, Development Sciences Quality and Director, Global Development Sciences Quality and Regulatory Compliance at BioMarin Pharmaceuticals, Director, Clinical Quality Management at Medivation Inc., Head, Quality Assurance and Regulatory Compliance at Naryx Pharma, and Associate Director Clinical Compliance and Training, Clinical Research and Development at Baxter BioScience. Dr. Cruz received his Doctor of Veterinary Medicine (DVM) from Balagtas College of Veterinary Medicine.